GO:0097191 extrinsic apoptotic signaling pathway: Death Receptor-Mediated Apoptosis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097191 describes the series of molecular signals that start at the cell surface, either when a ligand binds a death receptor or when a ligand is withdrawn from a dependence receptor, and culminate in activation of the execution phase of apoptosis.
• The extrinsic pathway is initiated by death ligands such as FASLG, TRAIL, and TNF, which engage FAS, TRAIL receptors, and TNFR1, leading to DISC formation and caspase-8 activation.
• Caspase-8 cleaves BID to connect the extrinsic pathway to the intrinsic mitochondrial pathway, amplifying apoptotic signaling in many cell types.
• Dysregulation of extrinsic apoptosis contributes to cancer progression, immune evasion, and resistance to therapy, making it a major target for anticancer drug development.
• The pathway is modulated by E3 ubiquitin ligases and deubiquitinases that control the stability and activity of TRAIL pathway components.
• Intracellular glycosylation and histone deacetylase inhibitors can modulate extrinsic apoptotic signaling, revealing layers of regulation beyond ligand-receptor interactions.
Description
The extrinsic apoptotic signaling pathway (GO:0097191) is a biological process that transmits death signals from the cell surface to the intracellular apoptotic machinery. It begins when a ligand binds to a cell surface receptor, such as FAS, TRAIL receptors, or TNFR1, or when a ligand is withdrawn from a dependence receptor, and it ends when the execution phase of apoptosis is triggered. This pathway is essential for tissue homeostasis, immune surveillance, and elimination of damaged or infected cells. Because defects in extrinsic apoptosis allow cancer cells to survive and resist therapy, the pathway is a major focus of anticancer drug discovery. Understanding its molecular steps, regulatory nodes, and crosstalk with the intrinsic pathway is critical for researchers developing targeted therapies and CRISPR-based disease models.
extrinsic apoptotic signaling pathway At A Glance
| GO ID | GO:0097191 |
|---|---|
| GO term | extrinsic apoptotic signaling pathway |
| Ontology | biological_process |
| Synonym | death receptor-mediated apoptosis; extrinsic apoptosis; extrinsic apoptotic pathway; extrinsic apoptotic signaling pathway in presence of ligand; extrinsic apoptotic signalling pathway |
| Major function | Transduces extracellular death signals from cell surface receptors to activate the execution phase of apoptosis |
| Definition | The series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell; starts with ligand binding or ligand withdrawal from a cell surface receptor and ends when the execution phase of apoptosis is triggered |
| Key receptors | FAS, TRAIL receptors (TNFRSF10A/B), TNFR1 |
| Key ligands | FASLG, TNFSF10 (TRAIL), TNF |
| Downstream effectors | Caspase-8, caspase-10, caspase-3, caspase-7, BID |
What Is GO:0097191?
GO:0097191, the extrinsic apoptotic signaling pathway, is defined as the series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with either a ligand binding to a cell surface receptor, or a ligand being withdrawn from a cell surface receptor (as in signaling by dependence receptors), and ends when the execution phase of apoptosis is triggered. It is synonymous with death receptor-mediated apoptosis, extrinsic apoptosis, and extrinsic apoptotic pathway.
Why Is extrinsic apoptotic signaling pathway Important in Cell Biology?
The extrinsic apoptotic signaling pathway is a central mechanism for eliminating unwanted cells and is frequently dysregulated in human disease. In cancer, evasion of extrinsic apoptosis contributes to tumor survival, immune escape, and resistance to chemotherapy and targeted agents. In β-thalassemia, altered extrinsic apoptotic signaling during definitive erythropoiesis affects red blood cell production and disease severity. Because this pathway is amenable to therapeutic modulation, it is a high-priority target for drug development and for functional genomics studies using CRISPR screens.
• Controls immune surveillance by enabling cytotoxic lymphocytes to kill target cells via death receptor ligands.
• Dysregulation promotes cancer cell survival and resistance to apoptosis-inducing therapies.
• Plays a role in normal and disordered erythropoiesis, including β-thalassemia.
• Caspase-8-mediated BID cleavage links extrinsic and intrinsic apoptotic pathways, amplifying cell death.
• E3 ubiquitin ligases and deubiquitinases modulate TRAIL-mediated extrinsic apoptosis, offering drug targets.
• Intracellular glycosylation regulates extrinsic apoptotic signaling, adding a metabolic layer of control.
• Histone deacetylase inhibitors can influence extrinsic pathway activity, linking epigenetics to apoptosis.
• Provides biomarkers and therapeutic targets for precision oncology.
• Enables CRISPR knockout and knock-in models to dissect gene function in apoptosis.
• Supports development of TRAIL-receptor agonists and other apoptosis-targeting drugs.
What Happens During extrinsic apoptotic signaling pathway?
Ligand binding and receptor activation
In simple terms: A death signal molecule outside the cell attaches to a receptor on the cell surface, switching the receptor on.
The extrinsic apoptotic signaling pathway begins when a ligand such as FASLG, TRAIL (TNFSF10), or TNF binds to its cognate cell surface receptor, including FAS, TRAIL receptors (TNFRSF10A/B), or TNFR1. This binding induces receptor trimerization and conformational changes that recruit adaptor proteins, most commonly FADD, to the cytoplasmic death domain of the receptor. In the case of dependence receptors, ligand withdrawal can also trigger apoptosis, but the best-characterized initiation mechanism is ligand binding to death receptors.
DISC formation and caspase-8 activation
In simple terms: The activated receptor assembles a platform that switches on an initiator caspase, which acts as the executioner's starter pistol.
Upon receptor activation, FADD and procaspase-8 (or procaspase-10) are recruited to form the death-inducing signaling complex (DISC). Within the DISC, procaspase-8 undergoes proximity-induced autoactivation, generating active caspase-8 heterotetramers. Active caspase-8 then cleaves downstream effector caspases, such as caspase-3 and caspase-7, initiating the execution phase of apoptosis. The DISC is a key regulatory node targeted by E3 ubiquitin ligases and deubiquitinases that modulate TRAIL-mediated extrinsic apoptosis.
Crosstalk with the intrinsic pathway via BID cleavage
In simple terms: The extrinsic pathway can call in the mitochondria for backup, amplifying the death signal.
Caspase-8 cleaves the BH3-only protein BID to generate truncated BID (tBID), which translocates to mitochondria and activates BAX/BAK, leading to cytochrome c release and apoptosome formation. This crosstalk between extrinsic and intrinsic pathways amplifies caspase activation and is particularly important in cells with low DISC efficiency. Histone deacetylase inhibitors can modulate this crosstalk, influencing antitumor activity.
Execution phase of apoptosis
In simple terms: The cell dismantles itself in a controlled way, packaging its contents for removal.
Active caspase-3 and caspase-7 cleave a broad spectrum of substrates, including PARP, ICAD, and cytoskeletal proteins, leading to DNA fragmentation, membrane blebbing, and formation of apoptotic bodies. The execution phase is the endpoint of GO:0097191 and is shared with the intrinsic apoptotic pathway. Dysregulation of this step can result in failed apoptosis and contribute to cancer and autoimmune disease.
Key Genes Involved in GO:0097191 extrinsic apoptotic signaling pathway
The following genes and proteins are central to the initiation, regulation, and execution of the extrinsic apoptotic signaling pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FAS | Death receptor that binds FASLG and triggers DISC formation | Target for knockout and point-mutation studies of receptor activation |
| FASLG | Ligand for FAS; induces receptor trimerization and apoptosis | Used in overexpression and ligand-withdrawal models |
| TNFRSF10A | TRAIL receptor 1 (DR4); mediates TRAIL-induced apoptosis | Knockout models to study TRAIL sensitivity |
| TNFRSF10B | TRAIL receptor 2 (DR5); mediates TRAIL-induced apoptosis | Key target for anticancer drug development |
| TNFSF10 | TRAIL ligand; activates DR4/DR5 | Overexpression models for apoptosis induction |
| FADD | Adaptor protein that recruits caspase-8 to the DISC | Essential for extrinsic pathway; knockout blocks apoptosis |
| CASP8 | Initiator caspase activated at the DISC | Central effector; knockout and point-mutation models |
| CASP10 | Initiator caspase in humans; can substitute for caspase-8 | Studied in caspase-8-deficient models |
| BID | BH3-only protein cleaved by caspase-8 to link to mitochondria | Knockout reduces crosstalk to intrinsic pathway |
| BAX | Pro-apoptotic effector activated by tBID | Knockout models for mitochondrial amplification |
| BAK | Pro-apoptotic effector activated by tBID | Knockout models for mitochondrial amplification |
| CASP3 | Executioner caspase cleaving downstream substrates | Knockout and activity assays for apoptosis execution |
| CASP7 | Executioner caspase cooperating with caspase-3 | Knockout models for apoptosis execution |
| TNF | Ligand for TNFR1; can induce apoptosis or survival | Context-dependent models of inflammation and apoptosis |
| TNFRSF1A | Receptor for TNF; activates both survival and death signals | Knockout models for TNF-induced apoptosis |
| CFLAR | Caspase-8 inhibitor; blocks extrinsic apoptosis | Overexpression models for apoptosis resistance |
| BIRC5 | Survivin; inhibits caspases and regulates apoptosis | Knockout and overexpression models for apoptosis modulation |
How Is extrinsic apoptotic signaling pathway Regulated?
The extrinsic apoptotic signaling pathway is tightly regulated at multiple levels. E3 ubiquitin ligases and deubiquitinases control the stability and activity of TRAIL pathway components, thereby modulating sensitivity to apoptosis. Intracellular glycosylation has emerged as a regulator of extrinsic apoptotic signaling, affecting receptor trafficking and DISC formation. Histone deacetylase inhibitors can shift the balance between extrinsic and intrinsic apoptotic pathways, influencing antitumor activity. Additionally, c-FLIP (CFLAR) acts as a key inhibitor by competing with caspase-8 for DISC binding. These regulatory mechanisms provide multiple entry points for therapeutic intervention and for CRISPR-based functional studies.
extrinsic apoptotic signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FAS | Autoimmune lymphoproliferative syndrome; cancer immune evasion | Knockout and point-mutation cell lines |
| CASP8 | Cancer resistance to apoptosis; immunodeficiency | Knockout and knock-in models |
| TNFRSF10B | Cancer sensitivity to TRAIL therapy | Overexpression and knockout models |
| BID | Crosstalk with intrinsic apoptosis in cancer | Knockout and point-mutation models |
| CFLAR | Cancer therapy resistance | Overexpression models |
Cancer and therapy resistance
Evasion of extrinsic apoptosis is a hallmark of cancer, allowing tumor cells to survive despite death receptor signaling. Downregulation of death receptors, overexpression of c-FLIP, and mutations in caspase-8 contribute to resistance to TRAIL-based therapies and chemotherapy. Targeting extrinsic apoptotic components, such as TRAIL receptor agonists and caspase activators, is an active area of anticancer drug development.
β-Thalassemia and erythropoiesis
Extrinsic apoptotic signaling plays a role during definitive erythropoiesis in normal individuals and in patients with β-thalassemia. Dysregulated apoptosis of erythroid precursors contributes to ineffective erythropoiesis and anemia in β-thalassemia, making the pathway a potential therapeutic target.
Autoimmune and inflammatory diseases
Defects in FAS/FASLG-mediated apoptosis can lead to autoimmune lymphoproliferative syndrome and impaired immune homeostasis. Conversely, excessive extrinsic apoptosis contributes to tissue damage in inflammatory conditions, highlighting the need for precise modulation.
From extrinsic apoptotic signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CASP8 block extrinsic apoptosis? | CASP8 knockout cell line |
| Does a point mutation in FAS death domain impair DISC formation? | FAS point-mutation knock-in |
| Can overexpression of CFLAR confer apoptosis resistance? | CFLAR overexpression cell line |
| Does tagging BID reveal its cleavage dynamics? | BID tagged knock-in |
| Which genes modulate TRAIL sensitivity? | CRISPR library screening |
| Does glycosylation regulate death receptor trafficking? | Glycosylation enzyme knockout |
How to Study the extrinsic apoptotic signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Annexin V/PI staining | Phosphatidylserine exposure and membrane integrity | Quantifying apoptosis after ligand treatment |
| Caspase-3/7 activity assay | Effector caspase activity | Measuring execution phase activation |
| Western blot | Cleavage of caspase-8, caspase-3, PARP, BID | Confirming pathway activation |
| Immunoprecipitation | DISC composition (FADD, caspase-8) | Studying receptor-proximal events |
| CRISPR knockout screen | Gene requirements for apoptosis sensitivity | Discovering novel regulators |
| Flow cytometry | Surface death receptor levels | Assessing receptor expression |
| Live-cell imaging | Caspase activation dynamics | Real-time apoptosis monitoring |
| Glycosylation analysis | Post-translational modifications of receptors | Studying regulation by glycosylation |
Apoptosis assays
Annexin V/PI staining, caspase-3/7 activity assays, and TUNEL staining are standard methods to quantify extrinsic apoptosis after ligand treatment or receptor activation. These assays measure phosphatidylserine exposure, caspase activity, and DNA fragmentation, respectively.
Western blot and immunoprecipitation
Western blotting detects cleavage of caspase-8, caspase-3, PARP, and BID, providing evidence of pathway activation. Immunoprecipitation can isolate the DISC to study FADD and caspase-8 recruitment.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens identify genes that modulate sensitivity to TRAIL or FASLG, revealing novel regulators of extrinsic apoptosis. These screens are powerful for discovering therapeutic targets and resistance mechanisms.
Flow cytometry and imaging
Flow cytometry quantifies surface death receptor levels and apoptosis markers, while live-cell imaging tracks caspase activation and mitochondrial permeabilization in real time. These methods are useful for studying receptor trafficking and glycosylation effects.
How CRISPR Can Be Used to Study GO:0097191 extrinsic apoptotic signaling pathway
Knockout
CRISPR knockout of CASP8, FADD, or BID abolishes or reduces extrinsic apoptosis, providing causal evidence for their roles. Knockout of negative regulators such as CFLAR sensitizes cells to death ligands. These models are essential for validating drug targets and understanding resistance mechanisms.
Point Mutation
Point mutations in the death domain of FAS or in caspase-8 catalytic sites can dissect structure-function relationships and mimic patient-derived mutations. CRISPR point-mutation knock-in allows precise modeling of disease-associated variants.
Knock-in
Tagged knock-in of BID or caspase-8 with fluorescent or affinity tags enables real-time tracking of cleavage and localization. Knock-in of reporter cassettes under endogenous promoters provides physiological expression for studying pathway dynamics.
Overexpression
Overexpression of TRAIL, FASLG, or CFLAR modulates apoptosis sensitivity and can model ligand-dependent or resistance states. Overexpression models are useful for screening drugs that overcome apoptosis resistance.
How EDITGENE Supports extrinsic apoptotic signaling pathway Research
Researchers studying extrinsic apoptotic signaling pathway-related genes often need to determine whether a candidate gene is causally involved in apoptosis initiation, regulation, or execution. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations to answer these questions.
Contact EDITGENE today to design your custom CRISPR model for extrinsic apoptotic signaling pathway research.
Frequently Asked Questions About extrinsic apoptotic signaling pathway
What is the extrinsic apoptotic signaling pathway?
It is the series of molecular signals that start at the cell surface when a ligand binds a death receptor (or is withdrawn from a dependence receptor) and end with activation of the execution phase of apoptosis.
What genes are involved in extrinsic apoptotic signaling pathway?
Key genes include FAS, FASLG, TNFRSF10A/B, TNFSF10, FADD, CASP8, CASP10, BID, BAX, BAK, CASP3, CASP7, CFLAR, and BIRC5.
What is the difference between intrinsic and extrinsic apoptosis?
The extrinsic pathway is triggered by extracellular ligands binding cell surface death receptors, while the intrinsic pathway is triggered by intracellular stress and mitochondrial permeabilization.
How is caspase-8 activated in extrinsic apoptosis?
Caspase-8 is recruited to the DISC via FADD, where proximity-induced autoactivation generates active caspase-8.
What is the role of BID in extrinsic apoptosis?
Caspase-8 cleaves BID to tBID, which activates BAX/BAK on mitochondria, linking extrinsic and intrinsic pathways.
How do E3 ubiquitin ligases regulate TRAIL-mediated apoptosis?
They control the ubiquitination and stability of TRAIL pathway components, thereby modulating sensitivity to apoptosis.
Can glycosylation affect extrinsic apoptotic signaling?
Yes, intracellular glycosylation modulates receptor trafficking and DISC formation, influencing apoptosis sensitivity.
What diseases are linked to defects in extrinsic apoptosis?
Cancer, autoimmune lymphoproliferative syndrome, β-thalassemia, and inflammatory diseases are associated with dysregulated extrinsic apoptosis.
How can CRISPR be used to study extrinsic apoptotic signaling?
CRISPR knockout, knock-in, point mutation, and overexpression models allow precise dissection of gene function in the pathway.
What methods measure extrinsic apoptosis?
Annexin V/PI staining, caspase activity assays, western blot, immunoprecipitation, flow cytometry, and live-cell imaging are commonly used.
Conclusion
The extrinsic apoptotic signaling pathway (GO:0097191) is a fundamental biological process that translates extracellular death signals into controlled cell death. Its dysregulation underlies cancer, autoimmune disease, and erythropoietic disorders, making it a prime target for therapeutic intervention. Advances in CRISPR-based models and functional genomics are accelerating the discovery of new regulators and drug targets within this pathway. Continued research into its molecular mechanisms and crosstalk with intrinsic apoptosis will inform next-generation therapies.
References
- 1. Raducka-Jaszul O et al.. 2020. Role of Extrinsic Apoptotic Signaling Pathway during Definitive Erythropoiesis in Normal Patients and in Patients with β-Thalassemia.. Int J Mol Sci 21(9) PMID: 32397135
- 2. Tian X et al.. 2024. Targeting apoptotic pathways for cancer therapy.. J Clin Invest 134(14) PMID: 39007268
- 3. Mustafa M et al.. 2024. Apoptosis: A Comprehensive Overview of Signaling Pathways, Morphological Changes, and Physiological Significance and Therapeutic Implications.. Cells 13(22) PMID: 39594587
- 4. Carneiro BA et al.. 2020. Targeting apoptosis in cancer therapy.. Nat Rev Clin Oncol 17(7):395-417 PMID: 32203277
- 5. Woo SM et al.. 2019. E3 ubiquitin ligases and deubiquitinases as modulators of TRAIL-mediated extrinsic apoptotic signaling pathway.. BMB Rep 52(2):119-126 PMID: 30638181
- 6. Matthews GM et al.. 2012. Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity.. Adv Cancer Res 116:165-97 PMID: 23088871
- 7. Seyrek K et al.. 2024. Modulation of extrinsic apoptotic pathway by intracellular glycosylation.. Trends Cell Biol 34(9):728-741 PMID: 38336591
- 8. Pistritto G et al.. 2016. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies.. Aging (Albany NY) 8(4):603-19 PMID: 27019364
